Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm trial of sunitinib with cisplatin and gemcitabine in first-line advanced urothelial carcinoma
2007-007591-42Phase 2Completed
- Sponsor
- Cardiff University
- Start
- Oct 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sunitinib, cisplatin and gemcitabine in transitional cell carcinoma (TCC) and bladder cancer, sponsored by Cardiff University. Primary endpoints: Progression-free survival at 6 months and Activity, safety and feasibility. Started Oct 2008; status: completed.
02
Drugs
sunitinibcisplatingemcitabine
03
Conditions
transitional cell carcinoma (TCC)bladder cancer
Beyond the preview
Go deeper on 2007-007591-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-007591-42.